X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-01-13 | RNAC | Springer Timothy A | Dir, 10% | P - Purchase | $17.47 | +20,967 | 9,391,955 | 0% | +$366,354 | |||||
| M | 2025-01-03 | RNAC | Kurtoglu Metin | CTO | S - Sale | $16.78 | -4,875 | 62,258 | -7% | -$81,790 | |||||
| M | 2025-01-03 | RNAC | Miljkovic Milos | Chief Medical Officer | S - Sale | $16.78 | -1,880 | 35,393 | -5% | -$31,542 | |||||
| M | 2025-01-03 | RNAC | Jewell Christopher M | Chief Scientific Officer | S - Sale | $16.78 | -2,550 | 53,490 | -5% | -$42,783 | |||||
| M | 2025-01-03 | RNAC | English Emily | Chief Operations Officer | S - Sale | $16.78 | -1,797 | 40,226 | -4% | -$30,149 | |||||
| M | 2025-01-03 | RNAC | Brunn Carsten | Pres, CEO | S - Sale | $16.78 | -17,271 | 204,096 | -8% | -$289,764 | |||||
| M | 2025-01-03 | RNAC | Davis Blaine | CFO | S - Sale | $16.78 | -7,989 | 94,811 | -8% | -$134,036 | |||||
| M | 2024-12-19 | RNAC | Springer Timothy A | Dir, 10% | P - Purchase | $18.49 | +52,189 | 9,368,388 | +1% | +$965,021 | |||||
| DM | 2024-12-09 | RNAC | Kurtoglu Metin | CTO | S - Sale+OE | $25.26 | -13,664 | 51,033 | -21% | -$345,134 | |||||
| DM | 2024-11-19 | RNAC | Kurtoglu Metin | CTO | S - Sale+OE | $16.78 | -38,689 | 51,033 | -43% | -$649,030 | |||||
| M | 2024-11-14 | RNAC | Springer Timothy A | Dir, 10% | P - Purchase | $17.07 | +431,940 | 9,316,199 | +5% | +$7,373,527 | |||||
| DM | 2024-11-14 | RNAC | Kurtoglu Metin | CTO | S - Sale+OE | $17.46 | -82,368 | 51,033 | -62% | -$1,438,038 | |||||
| DM | 2024-11-14 | RNAC | Miljkovic Milos | Chief Medical Officer | S - Sale+OE | $16.50 | -55,000 | 18,273 | -75% | -$907,533 | |||||
| DM | 2024-11-14 | RNAC | Jewell Christopher M | Chief Scientific Officer | S - Sale+OE | $16.79 | -52,115 | 25,940 | -67% | -$875,042 | |||||
| DM | 2024-10-02 | RNAC | Springer Timothy A | Dir, 10% | P - Purchase | $20.87 | +205,721 | 8,884,259 | +2% | +$4,293,545 | |||||
2024-08-12 | RNAC | Springer Timothy A | Dir, 10% | P - Purchase | $12.72 | +8,016 | 6,319,038 | 0% | +$101,968 | ||||||
| D | 2024-08-12 | RNAC | Barabe Timothy C | Dir | P - Purchase | $12.70 | +7,500 | 21,766 | +53% | +$95,250 | |||||
| M | 2024-01-17 | RNAC | Springer Timothy A | Dir, 10% | P - Purchase | $0.62 | +18,400 | 40,620,292 | 0% | +$11,442 | |||||
2024-03-18 | RNAC | Springer Timothy A | Dir, 10% | P - Purchase | $0.60 | +19,044 | 38,631,449 | 0% | +$11,398 | ||||||
| M | 2024-03-14 | RNAC | Springer Timothy A | Dir, 10% | P - Purchase | $0.56 | +1,185,872 | 38,612,405 | +3% | +$666,222 | |||||
2023-09-25 | SELB | Brunn Carsten | Pres, CEO | S - Sale | $1.06 | -2,932 | 783,081 | 0% | -$3,108 | ||||||
2023-09-25 | SELB | Traber Peter G | Chief Medical Officer | S - Sale | $1.06 | -705 | 451,826 | 0% | -$747 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |